J&J's S.M.A.R.T. Stent Journal Ad Implies Off-Label Use - FDA Says
This article was originally published in The Gray Sheet
Johnson & Johnson Cordis' placement of an advertisement for its S.M.A.R.T. biliary stent in the February, 1999 issue of the journal Endovascular Surgery, prompted an April 28 FDA warning letter.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.